Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $13.6 million.

  • Atara Biotherapeutics' Shares Outstanding (Diluted Average) rose 8167.69% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 8167.69%. This contributed to the annual value of $7.5 million for FY2024, which is 7677.05% up from last year.
  • Atara Biotherapeutics' Shares Outstanding (Diluted Average) amounted to $13.6 million in Q3 2025, which was up 8167.69% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Shares Outstanding (Diluted Average) ranged from a high of $104.0 million in Q1 2023 and a low of $4.2 million during Q2 2023
  • For the 4-year period, Atara Biotherapeutics' Shares Outstanding (Diluted Average) averaged around $39.1 million, with its median value being $10.9 million (2025).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first crashed by 9587.3% in 2023, then surged by 10039.07% in 2025.
  • Atara Biotherapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $102.0 million in 2022, then tumbled by 95.85% to $4.2 million in 2023, then skyrocketed by 76.77% to $7.5 million in 2024, then surged by 81.14% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $12.3 million for Q2 2025, and $10.9 million during Q1 2025.